Tislelizumab in conjunction with chemotherapy for the treatment of nasal metastasis from lung squamous cell carcinoma: a case report and literature review
Therapeutic Advances in Respiratory Disease · Published 2025-10-01 · DOI 10.1177/17534666251384018
Free full text
Authors being retrieved — see the publisher record. https://doi.org/10.1177/17534666251384018
Abstract
Cases of pulmonary squamous cell carcinoma (SCC) metastases to the nasal region are highly uncommon and frequently manifest with poor prognosis. However, the use of anti-programmed cell death protein 1 (PD-1) inhibitors in pulmonary SCC with nasal metastasis has not been documented. In this study, a case of pulmonary SCC metastasizing to the nose was discussed. Nasal nodules appeared in the patient; initially, these were considered benign lesions. It was determined following a pathological biopsy that the patient had nasal metastases of lung SCC. The lung tumor had decreased after two cycles of standard chemotherapy (paclitaxel + carboplatin); however, the nasal tumor continued to grow. Consider that nasal metastases are not responsive to chemotherapy. A multidisciplinary consultation believed that immunotherapy had potential benefits for metastatic tumors and decided to use a chemotherapy + immunotherapy regimen. The nasal metastatic tumor gradually returned to normal as a result of the combination of standard chemotherapy and immunotherapy (Tislelizumab) from the third cycle onward. After six cycles of combined treatment, the patient began maintenance monotherapy. During treatment, the patient’s condition remained stable without progression or distant metastasis. This case highlights the potential of combining anti-PD-1 therapy with standard chemotherapy as an effective salvage strategy for chemotherapy-refractory nasal metastases of pulmonary squamous cell carcinoma, thereby contributing to improved patient survival.
Abstract from DOAJ. Public domain (CC0 1.0).
Read the article at the publisher →
Publication details
- Year
- 2025
Related articles
- Advances in orphan drug development for alpha-1 antitrypsin deficiency: a 2025 update from the FDA and EMA · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of “aged” people with cystic fibrosis · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- The effectiveness of the AI-based RehabLung mobile rehabilitation system on cardiopulmonary function and user satisfaction in lung cancer patients undergoing thoracic surgery: a protocol for a two-arm randomized clinical trial · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Spontaneous pneumothorax-associated with genetic disorders · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Randomized, phase I studies to evaluate the safety, tolerability, and pharmacokinetics of an inhaled, TMEM16A potentiator, GDC-6988, in healthy subjects · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- Effects of dual bronchodilation on right ventricular function and troponin-I in newly diagnosed, moderate-to-severe chronic obstructive pulmonary disease: a prospective real-world observational study · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Bioequivalence of budesonide/glycopyrrolate/formoterol fumarate with a next-generation propellant versus hydrofluoroalkane-134a in healthy adults: phase I, randomized, double-blind, single-dose, partial-replicate, three-way cross-over lung exposure and total systemic exposure studies · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- Social risk factors in patients with cystic fibrosis: impacts on exacerbations, lung function, and BMI · Therapeutic Advances in Respiratory Disease · 2025 · Same journal
- Pulmonary tuberculosis during the developmental period contributes to COPD and pre-COPD in mid-to-late adulthood: a retrospective cohort study · Therapeutic Advances in Respiratory Disease · 2026 · Same journal
- The association between mental health, cognitive functioning, and health-related quality of life in adults with chronic nontuberculous mycobacterial pulmonary disease · Therapeutic Advances in Respiratory Disease · 2025 · Same journal